INmune Bio Inc. (INMB)’s Financial Results Comparing With Theravance Biopharma Inc. (NASDAQ:TBPH)

INmune Bio Inc. (NASDAQ:INMB) and Theravance Biopharma Inc. (NASDAQ:TBPH), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
INmune Bio Inc. N/A 0.00 10.99M -0.98 0.00
Theravance Biopharma Inc. 60.37M 21.13 215.52M -4.72 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of INmune Bio Inc. and Theravance Biopharma Inc.

Profitability

Table 2 has INmune Bio Inc. and Theravance Biopharma Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
INmune Bio Inc. 0.00% 0% 0%
Theravance Biopharma Inc. -357.00% -520.6% -60.6%

Liquidity

INmune Bio Inc.’s Current Ratio and Quick Ratio are 5.5 and 5.5 respectively. The Current Ratio and Quick Ratio of its competitor Theravance Biopharma Inc. are 3.3 and 3.1 respectively. INmune Bio Inc. therefore has a better chance of paying off short and long-term obligations compared to Theravance Biopharma Inc.

Analyst Ratings

In next table is given INmune Bio Inc. and Theravance Biopharma Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
INmune Bio Inc. 0 0 0 0.00
Theravance Biopharma Inc. 0 0 2 3.00

Theravance Biopharma Inc. on the other hand boasts of a $47.5 consensus price target and a 106.97% potential upside.

Insider and Institutional Ownership

INmune Bio Inc. and Theravance Biopharma Inc. has shares held by institutional investors as follows: 7.2% and 87.4%. About 16.3% of INmune Bio Inc.’s share are held by insiders. Competitively, Theravance Biopharma Inc. has 5.7% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
INmune Bio Inc. -7.25% 0% 0% 0% 0% -5.51%
Theravance Biopharma Inc. -0.37% -6.1% -8.46% -14.12% -7.96% -4.42%

For the past year INmune Bio Inc. was more bearish than Theravance Biopharma Inc.

Summary

On 6 of the 10 factors INmune Bio Inc. beats Theravance Biopharma Inc.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The companyÂ’s product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.